

## The Conformation of *de Novo* Designed Amphiphilic Peptides with Six or Nine L-2-(2,2,2-Trifluoroethyl)glycines as the Hydrophobic Amino Acid

Toru Arai,\* Takashi Imachi, Tamaki Kato, and Norikazu Nishino\*<sup>†,‡</sup>

Department of Applied Chemistry, Faculty of Engineering, Kyushu Institute of Technology,  
Tobata-ku, Kitakyushu 804-8550

<sup>†</sup>Institute for Fundamental Research of Organic Chemistry, Kyushu University, Higashi-ku, Fukuoka 812-8581

(Received August 2, 1999)

Amphiphilic 21-peptides with six and nine L-2-(2,2,2-trifluoroethyl)glycines as the hydrophobic amino acids and lysine and glutamic acid as the hydrophilic amino acids were synthesized. The CD spectra showed that these peptides with L-2-(2,2,2-trifluoroethyl)glycines took a random conformation in H<sub>2</sub>O. On the contrary, similar amphiphilic 21-peptides with leucine as the hydrophobic amino acids took a helical conformation in H<sub>2</sub>O. The peptides with L-2-(2,2,2-trifluoroethyl)glycines took a helical conformation in H<sub>2</sub>O containing a > 20% volume of 2,2,2-trifluoroethanol. These facts suggested the hydrophobic nature of the L-trifluoroethylglycines. The peptide with six L-2-(2,2,2-trifluoroethyl)glycines took a helical structure in methanol, however it slowly changed into the  $\beta$ -structure within 24 h. Interestingly, the peptide with nine L-2-(2,2,2-trifluoroethyl)glycines formed a stable helix under the same conditions. The peptide with nine L-2-(2,2,2-trifluoroethyl)glycines preferred a helical structure, probably because the assembling of the Tfeg side chains was more effective in forming its helix rather than the  $\beta$ -structure.

Recent progress on the *de novo* design and synthesis of polypeptides has opened a new area in biomimetic chemistry.<sup>1</sup> Polypeptides with super secondary structures, such as the assembled  $\alpha$ -helices,<sup>2</sup> artificial  $\beta$ -sheets,<sup>3</sup> and their three-dimensional complexes, have been successfully synthesized.<sup>1–7</sup> Not only the synthesis of these complex molecules, but recently, a protein-like function of the artificial peptides have been shown. For instance, some peptides have been found to change their conformation from  $\alpha$ -helices to the  $\beta$ -structure.<sup>4</sup> The enzyme-like catalysis of the peptides with the defined three-dimensional structure would be another recent example of the protein-like function.<sup>5</sup> Thus far, several concepts have been employed for the polypeptide architecture; the hydrogen bonding between the amide groups,<sup>3c</sup> the hydrophobic interaction between the amphiphilic peptides,<sup>2d</sup> Coulomb interaction of the amino acid side chains,<sup>2b,2c,2e</sup> the metal chelation,<sup>6</sup> the template-assistance to define the polypeptide super-structure,<sup>7</sup> and so on.

If some new artificial factor can be introduced during the *de novo* synthesis with the brand-new interaction between the amino acids, the possibility of an “artificial super-structure”, as described above, will be further expanded. With that in mind, multi-fluorinated amino acids should be highly hydrophobic,<sup>8–13</sup> and therefore, the amphiphilic peptide with such multi-fluorinated amino acids is very interesting. Moreover, fluorinated compounds sometimes gather with each other,

suggesting a negative affinity of the fluorocarbons with the hydrocarbon groups.<sup>9d,14</sup> The fluoroalkyl groups in the fluorinated polypeptides have the possibility of an attractive interaction with each other. Interestingly, a novel hydrogen-bond-like interaction with O–H/FC has recently been reported.<sup>15</sup> Though the fluorine atoms have often shown their unique effects in artificial biological molecules,<sup>8,9</sup> few have studied the character of polypeptides incorporating many multi-fluorinated amino acids.<sup>9d,13</sup> Herein, we wish to report on the syntheses and their solution conformation of the 21-residue peptides with six and nine L-2-(2,2,2-trifluoroethyl)glycine (Tfeg, (S)-H<sub>2</sub>NCH(CH<sub>2</sub>CF<sub>3</sub>)CO<sub>2</sub>H)<sup>10</sup> residues (**21Tfeg6** and **21Tfeg9**, Fig. 1). In their  $\alpha$ -helix structure, hydrophobic Tfeg would occupy one face of the polypeptide helix surface and the hydrophilic lysine (Lys) and glutamic acid (Glu) residues occupy the other face.<sup>16</sup> We wish to show the effect of the fluoroalkyl groups on the conformation of **21Tfeg6** and **21Tfeg9**, by a comparison with the amphiphilic peptides with leucine (Leu) residues instead of Tfeg (**21Leu6** and **21Leu9**, Fig. 1).<sup>17</sup>

### Results and Discussion

**Design and Synthesis of Tfeg-Containing Peptide.** For the helical peptide with a multi-fluorinated amino acid, L-2-(2,2,2-trifluoroethyl)glycine (Tfeg) was chosen for several reasons. (1) Tfeg can be easily synthesized from 2,2,2-trifluoroethanol (TFE),<sup>10</sup> in contrast to the lengthy synthesis of, for instance, 5,5,5,5',5',5'-hexafluoroleucine.<sup>11a</sup> (2) Tfeg can be easily obtained in the L-form by a simple enzymatic resolution.<sup>10</sup> (3) The helical structure can be expected for

# Present address: Department of Applied Chemistry, Faculty of Engineering, Kyushu Institute of Technology.



was chosen, which is selectively removable with Zn–AcOH.<sup>22</sup> Solution-phase fragment coupling between Boc–Ala–Tfeg–Ala–Lys(CIZ)–Ala–Tfeg–Ala–OH and H–Ala–Tfeg–Ala–Lys(CIZ)–Ala–Tfeg–Ala–OBzl was performed in CH<sub>2</sub>Cl<sub>2</sub>–TFE (10 : 3, v/v), which is known to dissolve various protected peptides (Fig. 3).<sup>23</sup> Because HPLC and FAB-MS showed that the obtained 14-peptide was sufficiently pure, this peptide was not thoroughly purified, but again coupled at its N-terminal. A fully protected 21-peptide (**6**) with six Tfeg residues was thus obtained. The protected 21-peptide with nine Tfeg residues (**9**) was similarly synthesized. These protected 21-peptides (**6** and **9**) were then treated with anhydrous hydrogen fluoride–10% anisole (v/v) to deprotect the Boc–, –OBzl, –CIZ, and –OcHex groups.<sup>24</sup> The crude 21-peptides **21Tfeg6** and **21Tfeg9** were purified by size-exclusion chromatography (Sephadex® G-25 eluting with 40% AcOH), in which these peptides were eluted as a single band. The elution volumes of **21Tfeg6** and **21Tfeg9** as well as those of **21Leu6** and **21Leu9** were similar. The FAB-MS (both low MS and high resolution MS, see Experimental Section) clearly indicated the molecular ion signals for both peptides, **21Tfeg6** (2091, [M+H]<sup>+</sup>) and **21Tfeg9** (2469, [M+H]<sup>+</sup>). HPLC analyses for these peptide showed that these peptide were obtained in high purity (see Experimental Section).

#### Solution Conformation of Tfeg-Containing Peptides.

In H<sub>2</sub>O (containing 3% HFIP), CD spectra indicated that the Tfeg-containing peptides **21Tfeg6** and **21Tfeg9** took the random coil structure with  $[\theta]_{\min}$  at 197 nm (Fig. 4, curves a and b); peptide concentration was 30  $\mu$ M (1 M = 1 mol dm<sup>–3</sup>).<sup>25</sup> These facts were in contrast to the facts that the Leu-containing amphiphilic peptides, **21Leu6** and **21Leu9**, showed typical CD spectra for the  $\alpha$ -helices in the same solvents (Fig. 4, curves c and d) with  $[\theta]_{\min}$  at 222 and 208 nm and  $[\theta]_{\max}$  at 192 nm.<sup>25,26</sup> The values of  $[\theta]_{\min}$  at 222 nm were –35000 deg cm<sup>2</sup> dmol<sup>–1</sup> for **21Leu6** and –29000 deg cm<sup>2</sup> dmol<sup>–1</sup> for **21Leu9**. The reasons why the Tfeg-containing peptides were of a distorted conformation in H<sub>2</sub>O are: (1) compared to




Fig. 3. Syntheses of the 21-peptides (**21Tfeg6** and **21Tfeg9**) via the stepwise fragment condensations.




Fig. 4. CD spectra of a) **21Tfeg6**, b) **21Tfeg9**, c) **21Leu6**, and d) **21Leu9** in H<sub>2</sub>O (3% HFIP). [Peptide] = 30  $\mu$ M.

the side chain of Leu (isobutyl group), the side chain of Tfeg (–CH<sub>2</sub>CF<sub>3</sub>) might be too hydrophobic; therefore, the side chain of Tfeg preferred to aggregate randomly in H<sub>2</sub>O than to arrange to form a helical structure; (2) compared to the side chain of Leu, the side chain of Tfeg might be sterically too small to isolate the amide groups from the solvent H<sub>2</sub>O; therefore, the solvent H<sub>2</sub>O could cleave the intramolecular hydrogen bonds.

In TFE, not only the Leu-containing peptides, **21Leu6** and **21Leu9**, but also the Tfeg-containing peptides, **21Tfeg6** and **21Tfeg9**, took the helical structure (Fig. 5) with  $[\theta]_{\min}$  at 218 and 205 nm. TFE is more hydrophobic than H<sub>2</sub>O;<sup>27</sup> therefore, the strong aggregation of Tfeg residues (the hydrophobic interaction between –CH<sub>2</sub>CF<sub>3</sub> groups) may be weakened,




Fig. 5. CD spectra of a) **21Tfeg6**, b) **21Tfeg9**, c) **21Leu6**, and d) **21Leu9** in TFE (3% HFIP). [Peptide] = 30  $\mu$ M.

resulting in the helix formation of **21Tfeg6** and **21Tfeg9**. The fact that hydrophobic TFE was necessary for the helix formation of **21Tfeg6** and **21Tfeg9** might suggest that Tfeg might be more hydrophobic than Leu.

As we have reported earlier, **21Leu6** and **21Leu9** assembled with each other to form the helix bundle structure, in which the Leu residues gathered inside via the hydrophobic interaction.<sup>17</sup> The ratio of  $[\theta]_{\text{ca. } 220}/[\theta]_{\text{ca. } 208}$  in the CD spectra, which is a marker of the compactness of the helices,<sup>28</sup> decreased in TFE (**21Leu6**; 0.86 in H<sub>2</sub>O and 0.65 in TFE, **21Leu9**; 0.91 in H<sub>2</sub>O and 0.64 in TFE). The  $\alpha$ -helicities ( $[\theta]_{\text{ca. } 220}$ ) also decreased in TFE.<sup>26</sup> These facts suggested that the bundle structure of **21Leu6** and **21Leu9** collapsed into monomeric helices in hydrophobic TFE. This fact may imply that the helices of **21Tfeg6** and **21Tfeg9** in TFE also exist as the solvated form, not as the assembled helix form.

A CD investigation of **21Tfeg6** in various contents of TFE in H<sub>2</sub>O further demonstrated that TFE stabilized the helical structure (Fig. 6, filled circle). Below a TFE content of 20% (v/v), **21Tfeg6** showed the CD spectrum of the random coil peptide with  $[\theta]_{\text{min}}$  at 197 nm as described above. Above a 20% content of TFE, **21Tfeg6** showed a helical CD spectrum with  $[\theta]_{\text{min}}$  at 205 and 218 nm (data not shown, but almost similar to that in TFE (Fig. 5, curve a)). TFE may probably solvate the Tfeg side chains; therefore, the helical structure of **21Tfeg6** may be stabilized. Interestingly, the  $\alpha$ -helicity evaluated with  $[\theta]_{218}$  was similar for the 20% TFE and 97% TFE. This fact might suggest that the 20% TFE amount was sufficient to solvate **21Tfeg6**. In contrast, the helical structure of **21Tfeg6** was hardly stabilized by MeOH. The  $[\theta]_{218}$  values of the CD spectra of **21Tfeg6** in various MeOH contents in H<sub>2</sub>O are shown in Fig. 6 (open circle, measured just after preparing the sample). In contrast to the circumstance in TFE–H<sub>2</sub>O, the helicity of **21Tfeg6** only gradually increased ( $[\theta]_{218}$  decreased) with an increase in MeOH. Interestingly,




Fig. 6. TFE (●) and MeOH (○)-induced helix structure for **21Tfeg6** evaluated by the  $[\theta]_{218}$  value in the CD spectra.  $[\mathbf{21Tfeg6}] = 30 \mu\text{M}$ .

the  $[\theta]_{218}$  in 97% MeOH was similar to that in 20–97% TFE. These facts suggest that the hydrophobic interaction of MeOH with **21Tfeg6** was not sufficient below 97% MeOH to stabilize its helical structure. This might suggest that the interaction of TFE with Tfeg may be effective in forming the helix structure.

Interestingly, the helical structure of **21Tfeg6** in MeOH was not stable with time. In Fig. 7, the CD spectra of **21Tfeg6** in MeOH is shown 5 min, 12 h, and 24 h after dissolving the peptide. Clearly the helical structure of **21Tfeg6** ( $[\theta]_{\text{min}}$  was 205 and 218 nm) in MeOH gradually changed into the  $\beta$ -structure ( $[\theta]_{\text{min}}$  was 215 nm).<sup>25</sup> However, the helical structure of not only **21Leu6** and **21Leu9** but also **21Tfeg9** were stable under the same conditions. In the  $\beta$ -structure, the side chains of the neighboring amino acids are located apart. Therefore, if **21Tfeg9** took the  $\beta$ -structure, the neighboring Tfeg residues in its –Glu–Tfeg–Tfeg–Lys– sequence would be separated from each other. One of the reasons why **21Tfeg9** preferred the helical structure and **21Tfeg6** tended to form  $\beta$ -structure in MeOH, may be because the Tfeg residues in the –Glu–Tfeg–Tfeg–Lys– sequence in **21Tfeg9** could be closely located in the helical structure, but separated in its  $\beta$ -structures. On the other hand, the Tfeg residues of **21Tfeg6** were not in the close proximity both in the helical and in the  $\beta$ -structure. The second possible reason why **21Tfeg9** preferred the helical structure in MeOH is the Coulomb interaction between the Glu and Lys side chains of **21Tfeg9**. The salt bridge between these residue may stabilize its helical structure. Thus, the unstable helical structure of **21Tfeg6** in MeOH slowly transformed into the  $\beta$ -structure.<sup>4</sup> The fact that the **21Tfeg9** formed a stable helix in MeOH, while **21Tfeg6** formed an unstable helix, also suggested that the Tfeg side chains tend to attract each other.

As a conclusion, the amphiphilic peptide with Tfeg residues **21Tfeg6** and **21Tfeg9** had a random structure in




Fig. 7. CD spectra of **21Tfeg6** in a) TFE, b) MeOH (after 5 min), c) MeOH (after 12 h), d) MeOH (after 24 h).  $[\mathbf{21Tfeg6}] = 30 \mu\text{M}$ .

H<sub>2</sub>O, though **21Leu6** and **21Leu9** had a helical structure under the same conditions. In a > 20% TFE content in H<sub>2</sub>O, **21Tfeg6** and **21Tfeg9** showed a helical structure. These Tfeg-containing peptides were partially helical in MeOH–H<sub>2</sub>O, however, the large content of MeOH was necessary to stabilize the helical structure in this case. The helical **21Tfeg6** in MeOH slowly changed into the  $\beta$ -structure, however, the helical **21Tfeg9** in MeOH did not change its structure under the same conditions. The peptide with successive Tfeg residues **21Tfeg9** (–Glu–Tfeg–Tfeg–Lys– sequence) did not tend to transform into the  $\beta$ -structure, which may be because the assembling of the Tfeg side chains may be more effective in forming its helical structure rather than the  $\beta$ -structure. Because the side chains of Tfeg residue may tend to gather with each other, this nature might be beneficial for the design of a sophisticated three-dimensional structure of artificial peptides.

### Experimental

**Analytical Methods.** An HPLC analysis was carried out using a Hitachi L-7100 intelligent pump equipped with a Hitachi L-4200 UV-vis detector and a Hitachi D-7500 chromatointegrator. The analysis was performed on a Wakosil<sup>®</sup> 5C4 column (4.6 × 150 mm) eluting with a linear gradient of a) CH<sub>3</sub>CN/H<sub>2</sub>O/TFA = 37/63/0.1 to 100/0/0.1 (v/v/v) or b) CH<sub>3</sub>CN/H<sub>2</sub>O/TFA = 0/100/0.1 to 100/0/0.1 (v/v/v) over 30 min at flow rate of 1.0 ml min<sup>–1</sup> with detection at 220 nm. Size exclusion chromatography was performed with a Sephadex<sup>®</sup> G-25 column (2.0 × 76 cm) eluting with 40% AcOH. FAB-MS spectra were obtained with a JEOL DX-300 or SX-102 mass spectrometer. High-resolution MS spectra (HIMS) were calibrated with CsI. The CD spectra were recorded on a JASCO J-500 or J-720 spectropolarimeter using a quartz cell of 1 mm pathlength at 25 °C using a 30  $\mu$ M peptide concentration. All CD samples contained 3% (v/v) HFIP. All CD samples were measured just after preparing each sample, unless otherwise noted. The Cotton effect was evaluated by the molar ellipticity [ $\theta$ ] per residue.

**Materials.** 2-(2,2,2-Trifluoroethyl)glycine (Tfeg) was synthesized and enzymatically resolved into its L-form according to the literature.<sup>10</sup> The amino acid derivatives and the reagents for the peptide synthesis were purchased from Peptide Institute Inc. and Watanabe Chemical Industries, Ltd. Other reagents and solvents were purchased from Wako Pure Chemical Industries, Ltd.

**Boc-Ala-Tfeg-Ala-OTce (1).** The dicyclohexylamine salt of Boc-Tfeg-OH (1.8 g, 4.0 mmol) and HCl·H-Ala-OTce (1.2 g, 4.5 mmol, synthesized from Boc-Ala-OH and 2,2,2-trichloroethanol with EDC/4-dimethylaminopyridine method,<sup>22</sup> then Boc protection was removed with HCl/dioxane<sup>29</sup> were suspended in 30 ml of DMF, then EDC·HCl (1.2 g, 6.0 mmol), HOBt·H<sub>2</sub>O (0.77 g, 5.0 mmol), and Et<sub>3</sub>N (0.63 ml, 4.5 mmol) were added at 0 °C.<sup>21</sup> The mixture was stirred at room temperature overnight and then evaporated. The remained oil was dissolved in ethyl acetate and the organic layer was successively washed with aqueous NaHCO<sub>3</sub> and aqueous citric acid. After evaporation, Boc-Tfeg-Ala-OTce was almost quantitatively obtained, which was pure enough for further synthesis. The successive coupling of Boc-Ala-OH with HCl·H-Tfeg-Ala-OTce (generated from Boc-Tfeg-Ala-OTce and HCl/dioxane) was similarly performed. After a work up, **1** was solidified by adding ethyl ether/petroleum ether (yield 1.8 g, 3.4 mmol, 85%). FAB-MS (3-nitrobenzyl alcohol), 530 ([M+H]<sup>+</sup>), 552 ([M+Na]<sup>+</sup>).

**Boc-Lys(CIZ)-Ala-Tfeg-Ala-OTce (2).** The coupling of Boc-Lys(CIZ)-OH (0.33 g, 0.80 mmol) with HCl·H-Ala-Tfeg-Ala-OTce (0.36 g, 0.77 mmol, generated from **1** and HCl/dioxane) was similarly performed and the crude product was chromatographed over silica gel (CHCl<sub>3</sub>–3% MeOH) giving **2** as an oil (0.50 g, 0.60 mmol, 78% yield). FAB-MS (3-nitrobenzyl alcohol), 828 ([M+H]<sup>+</sup>), 850 ([M+Na]<sup>+</sup>).

**Boc-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OTce (3).** To the AcOH (12 ml) solution of **1** (0.32 g, 0.60 mmol), 2.3 g of Zn powder was added and the mixture was stirred for 5 h. After filtration, the solvent was evaporated and then washed with aqueous citric acid to give 0.25 g (0.60 mmol) of Boc-Ala-Tfeg-Ala-OH as an oil. This oil was dissolved in 10 ml of DMF; then, TFA-Lys(CIZ)-Ala-Tfeg-Ala-OTce (0.47 g, 0.56 mmol, generated from **2** and TFA), DIEA (0.10 ml, 0.60 mmol), HOBt·H<sub>2</sub>O (0.11 g, 0.70 mmol), and EDC·HCl (0.15 g, 0.80 mmol) were added at 0 °C. The mixture was stirred at 0 °C for 24 h and then evaporated. After work-up, **3** was obtained in 93% yield (0.58 g, 0.52 mmol), which was pure enough for further synthesis. HPLC (gradient a), 20.7 min. FAB-MS (2,2'-dithiodiethanol), 1110 ([M+H]<sup>+</sup>), 1132 ([M+Na]<sup>+</sup>).

**Boc-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OBzl (4).** Starting from HCl·H-Ala-OBzl, **4** was synthesized in a manner similar to **3**. HPLC, 19.9 min. FAB-MS (2,2'-dithiodiethanol), 1067 ([M+H]<sup>+</sup>), 1089 ([M+Na]<sup>+</sup>).

**Boc-(Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala)<sub>3</sub>-OBzl (5).** The HFIP (0.20 ml) solution of **3** (0.13 g, 0.12 mmol) was diluted with 2.0 ml of AcOH, then Zn powder (0.13 g) was added and the mixture was stirred for 3 h. After filtration, the mixture was concentrated and solidified with the addition of aqueous citric acid. Boc-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OH was thus obtained as a solid (0.12 g, 0.12 mmol), which was pure enough for further synthesis. This solid was dissolved by adding CH<sub>2</sub>Cl<sub>2</sub> (10 ml) and TFE (3 ml),<sup>23</sup> then TFA·H-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OBzl (0.11 g, 0.10 mmol, generated from **4** and TFA), DIEA (17  $\mu$ l, 0.10 mmol), HOBt·H<sub>2</sub>O (18 mg, 0.12 mmol), and EDC·HCl (29 mg, 0.15 mmol) were added at 0 °C. The mixture was stirred at 0 °C for 36 h. After a work-up, 0.20 g (0.10 mmol) of the protected 14-peptide Boc-(Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala)<sub>2</sub>-OBzl was obtained, which was pure enough for further synthesis. HPLC (gradient a), 24.8 min. FAB-MS (3-nitrobenzyl alcohol), 1948 ([M+Na]<sup>+</sup>). Similarly, Boc-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OH (76 mg, 78  $\mu$ mol) was again coupled with TFA·H-(Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala)<sub>2</sub>-OBzl (0.12 g, 60  $\mu$ mol, generated from the above 14-peptide and TFA) in CH<sub>2</sub>Cl<sub>2</sub> (12 ml)–TFE (5 ml) using DIEA (14  $\mu$ l, 78  $\mu$ mol), HOBt·H<sub>2</sub>O (14 mg, 90  $\mu$ mol), and EDC·HCl (19 mg, 0.10 mmol). After a work-up, the protected 21-peptide (**5**) was solidified with the addition of aqueous NaHCO<sub>3</sub>, yielding 0.17 g (60  $\mu$ mol). This material was also pure enough for further synthesis. FAB-MS (3-nitrobenzyl alcohol), 2807 ([M+Na]<sup>+</sup>).

**H-(Ala-Tfeg-Ala-Lys-Ala-Tfeg-Ala)<sub>3</sub>-OH (21Tfeg6).** The protected 21-peptide **5** (88 mg, 32  $\mu$ mol) was treated with anhydrous HF (9.0 ml)–anisole (1.0 ml) at 0 °C for 1 h.<sup>24</sup> The fully deprotected peptide was washed, lyophilized, and then purified by size exclusion chromatography (Sephadex<sup>®</sup> G-25) eluting with 40% AcOH. The peptide eluted as a single band. The appropriate fractions were collected, yielding 20 mg (9.6  $\mu$ mol) of **21Tfeg6**. FAB-MS (2,2'-dithiodiethanol), 2090 ([M+H]<sup>+</sup>). HIMS, Found: *m/z* 2089.8920. Calcd for C<sub>78</sub>H<sub>123</sub>N<sub>24</sub>O<sub>22</sub>F<sub>18</sub>: *M*, 2089.8955. HPLC (gradient b), 16.4 min.

**Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-OTce (6).** The di-

cyclohexylamine salt of Boc-Tfeg-OH (0.87 g, 2.0 mmol) and HCl-H-Lys(CIZ)-OTce (1.1 g, 2.2 mmol) were suspended in 10 ml of DMF, then EDC·HCl (0.58 g, 3.0 mmol), HOBt·H<sub>2</sub>O (0.37 g, 2.4 mmol), and Et<sub>3</sub>N (0.30 ml, 2.2 mmol) were added at 0 °C. The mixture was stirred at room temperature overnight and then evaporated. After a work-up, almost pure Boc-Tfeg-Lys(CIZ)-OTce was quantitatively obtained. Next, a similar coupling of Boc-Tfeg-OH with HCl-H-Tfeg-Lys(CIZ)-OTce gave Boc-Tfeg-Tfeg-Lys(CIZ)-OTce in 65% yield. The successive coupling of Boc-Glu(OcHex)-OH with HCl-H-Tfeg-Tfeg-Lys(CIZ)-OTce gave **6** in 96% yield. FAB-MS (3-nitrobenzyl alcohol), 1037 ([M+H]<sup>+</sup>).

**Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala-OTce (7).** The treatment of **6** (0.42 g, 0.40 mmol) in 8.0 ml of AcOH with Zn (1.6 g) gave Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-OH quantitatively. The coupling of this tetrapeptide (0.40 mmol) with HCl-H-Ala-Tfeg-Ala-OTce (0.16 g, 0.34 mmol) was performed in 4.0 ml of DMF with DIEA (66 µl, 0.40 mmol), HOBt·H<sub>2</sub>O (92 mg, 0.60 mmol), and EDC·HCl (0.11 g, 0.60 mmol) at 0 °C for 24 h. After work-up, **7** was obtained as an oil (0.41 g, 0.31 mmol, 91%). HPLC (gradient a), 25.1 min. FAB-MS (2,2'-dithiodiethanol), 1318 ([M+H]<sup>+</sup>).

**Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala-OBzl (8).** The coupling of Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-OH with HCl-H-Ala-Tfeg-Ala-OBzl was similarly performed to give **8**. HPLC (gradient a), 24.5 min. FAB-MS (2,2'-dithiodiethanol), 1291 ([M+H]<sup>+</sup>).

**Boc-(Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala-OBzl)<sub>3</sub> (9).** To the TFE (0.50 ml)-CH<sub>2</sub>Cl<sub>2</sub> (1.0 ml) solution of Boc-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala-OH (generated from **7** (30 mg, 25 µmol) and Zn/AcOH), TFA·H-Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala-OBzl (generated from **8** (32 mg, 25 µmol) and TFA), DIEA (4.0 µl, 20 µmol), HOBt·H<sub>2</sub>O (5.0 mg, 30 µmol), and EDC·HCl (7.0 mg, 37 µmol) were added and the mixture was stirred at 0 °C for 48 h. After a work-up, the protected 14-peptide Boc-(Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala)<sub>2</sub>-OBzl (39 mg, 17 µmol) was obtained. This material was pure enough for further synthesis. HPLC, 29.8 min. FAB-MS (3-nitrobenzyl alcohol), 2368 ([M+Na]<sup>+</sup>). Next, Boc-Ala-Tfeg-Ala-Lys(CIZ)-Ala-Tfeg-Ala-OH (15 mg, 13 µmol) was coupled with TFA·H-(Glu(OcHex)-Tfeg-Tfeg-Lys(CIZ)-Ala-Tfeg-Ala)<sub>2</sub>-OBzl (23 mg, 10 µmol) in TFE-CH<sub>2</sub>Cl<sub>2</sub>, giving 32 mg (9.4 µmol) of the protected 21-peptide (**9**). This material was pure enough for further synthesis. FAB-MS (3-nitrobenzyl alcohol), 3434 ([M+Na]<sup>+</sup>).

**H-(Glu-Tfeg-Tfeg-Lys-Ala-Tfeg-Ala)<sub>3</sub>-OH (21Tfeg9).** The protected 21-peptide **9** (41 mg, 12 µmol) was treated with HF (9.0 ml)-anisole (1.0 ml) at 0 °C for 1 h. The fully deprotected peptide was washed, lyophilized, and then purified by size exclusion chromatography (Sephadex<sup>®</sup> G-25) eluted with 40% AcOH. The peptide eluted as a single band. The appropriate fractions were collected, yielding 14 mg (5.7 µmol) of **21Tfeg9**. FAB-MS (2,2'-dithiodiethanol), 2469 ([M+H]<sup>+</sup>), HIMS. Found: *m/z* 2467.8781. Calcd for C<sub>87</sub>H<sub>126</sub>N<sub>24</sub>O<sub>28</sub>F<sub>27</sub>: *M*, 2467.8741. HPLC (gradient b), 17.6 min.

Financial support of this work by a Grant-in-Aid for Scientific Research on Priority Areas No. 09217246 from the Ministry of Education, Science, Sports and Culture, is gratefully acknowledged. We thank Prof. Hideo Akisada at Kyushu

Kyoritsu University for the CD measurements.

## References

- For recent reviews, see: a) S. F. Bets, J. W. Bryson, and W. F. DeGrado, *Curr. Opin. Struct. Biol.*, **5**, 457 (1995). b) J. P. Schneider and J. W. Kelly, *Chem. Rev.*, **95**, 2169 (1995). c) N. Voyer, *Top. Curr. Chem.*, **184**, 1 (1997), and references cited therein.
- a) N. E. Zhou, C. M. Kay, and R. S. Hodges, *Biochemistry*, **31**, 5739 (1992). b) S. Nautiyal, D. N. Woolfson, D. S. King, and T. Alber, *Biochemistry*, **34**, 11643 (1995). c) R. Fairman, H.-G. Chao, T. B. Lavoie, J. J. Villafranca, G. R. Matsueda, and J. Novotny, *Biochemistry*, **35**, 2824 (1996). d) S. F. Betz and W. F. DeGrado, *Biochemistry*, **35**, 6955 (1996). e) J. P. Schneider, J. D. Lear, and W. F. DeGrado, *J. Am. Chem. Soc.*, **119**, 5742 (1997). f) H. Ueda, S. Kimura, and Y. Imanishi, *Chem. Commun.*, **1998**, 363. g) J. J. Skalicky, B. R. Gibney, F. Rabanal, R. J. B. Urbauer, P. L. Dutton, and J. Wand, *J. Am. Chem. Soc.*, **121**, 4941 (1999), and references cited therein.
- a) J. S. Nowick, S. Mahrus, E. M. Smith, and J. W. Ziller, *J. Am. Chem. Soc.*, **118**, 1066 (1996). b) C. L. Nesloney and J. W. Kelly, *J. Am. Chem. Soc.*, **118**, 5836 (1996). c) C. N. Kristen and T. H. Schrader, *J. Am. Chem. Soc.*, **119**, 12061 (1997). d) N. Yamada, K. Ariga, M. Naito, K. Matsubara, and E. Koyama, *J. Am. Chem. Soc.*, **120**, 12192 (1998). e) T. D. Clark, J. M. Buriak, K. Kobayashi, M. P. Isler, D. E. McRee, and M. R. Ghadiri, *J. Am. Chem. Soc.*, **120**, 8949 (1998), and references cited therein.
- H. Mihara and Y. Takahashi, *Curr. Opin. Struct. Biol.*, **7**, 501 (1997), and references cited therein.
- For instance, see: a) Y. Fukushima, *Bull. Chem. Soc. Jpn.*, **69**, 2269 (1996). b) K. S. Broo, H. Nilsson, J. Nilsson, and L. Balzer, *J. Am. Chem. Soc.*, **120**, 10287 (1998).
- a) M. Lieberman, M. Tabet, and T. Sasaki, *J. Am. Chem. Soc.*, **116**, 5035 (1994). b) G. K. Walkup and B. Imperiali, *J. Am. Chem. Soc.*, **118**, 3053 (1996). c) K. Suzuki, H. Hiroaki, D. Kohda, H. Nakamura, and T. Tanaka, *J. Am. Chem. Soc.*, **120**, 13008 (1998), and references cited therein.
- a) P. E. Dawson and S. B. H. Kent, *J. Am. Chem. Soc.*, **115**, 7263 (1993). b) K. Rose, *J. Am. Chem. Soc.*, **114**, 30 (1994). c) N. Nishino, T. Kato, T. Murata, H. Nakayama, T. Arai, T. Fujimoto, H. Yamamoto, and S. Yoshikawa, *Chem. Lett.*, **1996**, 49. d) P. Dummy, M. Keller, D. E. Ryan, B. Rohwedder, T. Wöhr, and M. Mutter, *J. Am. Chem. Soc.*, **119**, 918 (1997), and references cited therein.
- For recent reviews, see: a) "Fluorine-Containing Amino Acids: Synthesis and Properties," ed by V. P. Kukhar" and V. A. Soloshonok, John Wiley & Sons, Chichester (1995). b) "Biomedical Frontiers of Fluorine Chemistry in ACS Symp. Ser., 639," ed by I. Ojima, J. R. McCarthy, and J. T. Welch, American Chemical Society, Washington, D.C. (1996).
- a) W. H. Vine, K.-h. Hsieh, and G. R. Marshall, *J. Med. Chem.*, **24**, 1043 (1981). b) K.-h. Hsieh, P. Needleman, and G. R. Marshall, *J. Med. Chem.*, **30**, 1097 (1987). c) S. Oiki, R. E. Kooper, II, and O. S. Anderson, *Biophys. J.*, **66**, 1823 (1994). d) T. Arai, T. Imachi, T. Kato, H. I. Ogawa, T. Fujimoto, and N. Nishino, *Bull. Chem. Soc. Jpn.*, **69**, 1383 (1996). e) R. Keese and C. Hinderling, *Synthesis*, **1996**, 695. f) M. K. Eberle, R. Keese, and H. Stoeckli-Evans, *Helv. Chim. Acta*, **81**, 182 (1998).
- T. Tsushima, S. Kawada, S. Ishihara, N. Uchida, O. Shiratori, J. Higaki, and M. Hirata, *Tetrahedron*, **44**, 5375 (1998).
- a) D. F. Loncrini and H. M. Walborsky, *J. Org. Chem.*, **7**, 369 (1964). b) D. Bunita and M. Hudlicky, *J. Fluorine Chem.*, **16**, 301 (1980). c) N. Muller, *J. Fluorine Chem.*, **36**, 163 (1987). d) P.

- Bravo, S. Capelli, S. V. Meille, F. Viani, M. Zanda, V. P. Kukhar', and V. A. Soloshonok, *Tetrahedron: Asymmetry*, **5**, 2009 (1994). e) W. Holloweck and K. Burger, *J. Pract. Chem.*, **337**, 391 (1995).
- 12 I. Ojima, K. Kato, K. Nakahashi, T. Fuchigami, and M. Fujita, *J. Org. Chem.*, **54**, 4511 (1989).
- 13 a) S. K. Holmgren, K. M. Taylor, L. E. Bretscher, and R. T. Raines, *Nature*, **392**, 666 (1998). b) D. D. DesMarteau and V. Montanari, *Chem. Commun.*, **1998**, 2241. c) B. Koksche, H.-D. Jakubke, H. Wenschuh, K. Dietmeier, A. Starostin, A. Woolley, M. Dathe, G. Müller, M. Gußmann, H. -J. Hofmann, T. Michel, and K. Burger, "Proceedings of the 25th European Peptide Symposium," in press.
- 14 Y. Ishikawa, H. Kuwahara, and T. Kunitake, *J. Am. Chem. Soc.*, **116**, 5579 (1994).
- 15 T. J. Barbarich, C. D. Rithner, S. M. Miller, O. P. Anderson, and S. H. Strauss, *J. Am. Chem. Soc.*, **121**, 4280 (1999).
- 16 Abbreviations used are according to IUPAC-IUB Commission, *Eur. J. Biochem.*, **138**, 9 (1984). Other abbreviations: Tfeg, L-trifluoroethylglycine; Boc, *t*-butoxycarbonyl; ClZ, 2-chlorobenzyloxycarbonyl; OcHex, cyclohexyloxy; OBzl, benzyloxy; OTce, 2,2,2-trichloroethoxy; EDC·HCl, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; HOBt, 1-hydroxybenzotriazole; DIEA, *N,N*-diisopropylethylamine; DMF, *N,N*-dimethylformamide; TFE, 2,2,2-trifluoroethanol; HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; TFA, trifluoroacetic acid; CD, circular dichroism.
- 17 a) N. Nishino, Y. Sugita, and T. Fujimoto, *Peptide Chem.*, **1983**, 233 (1984). b) N. Nishino, H. Mihara, Y. Tanaka, and T. Fujimoto, *Tetrahedron Lett.*, **33**, 5767 (1992). c) N. Nishino, H. Mihara, T. Uchida, and T. Fujimoto, *Chem. Lett.*, **1993**, 53. d) H. Mihara, K. Tomizaki, N. Nishino, and T. Fujimoto, *Chem. Lett.*, **1993**, 1533.
- 18 P. C. Lyu, J. C. Sherman, A. Chen, and N. R. Kallenbach, *Proc. Natl. Acad. Sci. U.S.A.*, **88**, 5317 (1991).
- 19 W. L. Jolly, "The Principles of Inorganic Chemistry," McGraw-Hill, New York (1976).
- 20 D. F. Loncrini and R. Filler, in "Advances in Fluorine Chemistry," Butterworths, London (1972), Vol. 6, pp. 43—67.
- 21 W. König and R. Geiger, *Chem. Ber.*, **103**, 2024 (1970).
- 22 M. K. Dhaon, R. K. Olsen, and K. Ramasamy, *J. Org. Chem.*, **47**, 1962 (1982).
- 23 a) M. Narita, S. Isokawa, S. Honda, H. Umeyama, H. Kakei, and S. Obana, *Bull. Chem. Soc. Jpn.*, **62**, 773 (1989). b) C. G. Fields and G. B. Fields, in "Peptide Synthesis Protocols, Methods in Molecular Biology," ed by M. W. Pennington and B. M. Dunn, Humana Press, Totowa (1994), Vol. 35, pp. 29—40.
- 24 S. Sakakibara and S. Shimonishi, *Bull. Chem. Soc. Jpn.*, **38**, 1412 (1965).
- 25 S. Y. Venyaminov and J. T. Yang, in "Circular Dichroism and the Conformational Analysis of Biomolecules," ed by G. D. Fasman, Plenum, New York (1996), pp. 69—107. References cited therein.
- 26 J. M. Scholtz, H. Qian, E. J. York, J. M. Stewart, and R. L. Baldwin, *Biopolymers*, **31**, 1463 (1991).
- 27 C. A. Rohl, A. Chakraborty, and R. L. Baldwin, *Protein Sci.*, **5**, 2623 (1996).
- 28 a) C. García-Echeverría, *J. Am. Chem. Soc.*, **116**, 6031 (1994). b) T. Arai, K. Kobata, H. Mihara, T. Fujimoto, and N. Nishino, *Bull. Chem. Soc. Jpn.*, **68**, 1989 (1995).
- 29 F. C. McKay and W. F. Albertson, *J. Am. Chem. Soc.*, **79**, 4686 (1957).